CAR-T & Cellular Therapy Focus

Explore the latest updates and expert interviews

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Legend Biotech. This supporters no influence over the production of the content.

Latest videos Videos by disease NK-cell therapy Features Videos by topic Podcasts Expert editorial board

Welcome to CAR-T & Cellular Therapy Focus

Explore the latest updates in this field by hematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.

CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

Videos by Disease

Multiple Myeloma
Lymphoma
ALL
AML
CLL
MDS
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
2:02
Improving treatment options for patients with R/R myeloma: immunotherapies & CELMoDs
Rakesh Popat • 12 May 2023
2:38
Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more
Maria-Victoria Mateos • 12 May 2023
2:49
Approaching lenalidomide-refractory multiple myeloma: unmet needs and ongoing trials
Luciano Costa • 13 May 2023
View All Videos
4:05
Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCL
Roni Shouval • 27 Apr 2023
2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
2:13
Psychosocial experiences in patients with DLBCL receiving CAR-T therapy vs other therapies
Lorna Warwick • 24 Apr 2023
0:58
The benefit of CAR-T therapy over autoSCT in 3L DLCBL & the promise of bispecifics in this setting
Marjolein van der Poel • 25 Apr 2023
View All Videos
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
View All Videos
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
10:17
Updates in AML
David Sallman et al. • 6 Jan 2023
1:21
The challenge of age in SCT & cellular therapy, and introducing cellular therapy in earlier LOT
Didier Blaise • 24 Apr 2023
1:30
Insights into NKG2D-targeting CAR-T cells in R/R AML
David Sallman • 20 Mar 2023
View All Videos
1:46
Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells
John Gribben • 10 Feb 2023
8:18
CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
John Gribben • 10 Feb 2023
3:12
Safety & efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Niranjan Shah • 15 Feb 2023
1:11
Challenges that have been faced with developing CAR-T products for CLL and future outlooks
Marco Ruella • 9 Feb 2023
View All Videos
1:16
Hurdles to CAR-T therapy for MDS & AML: T-cell fitness & lack of a uniform target antigen
David Sallman • 11 Dec 2022
1:55
Phase I/Ib safety study of PRGN-3006 UltraCAR-T in patients with R/R CD33-positive AML & HR-MDS
Nelli Bejanyan • 12 Dec 2022
1:31
The potential of bringing CAR-T therapy to MDS and challenges to overcome
Eric Padron • 9 Dec 2022
2:01
Strategies to manipulate the immune system in myeloid malignancies
Eunice Wang • 29 Sep 2022
View All Videos

Videos by Topic

Nursing
Clinical Practice
Policy
Treatment
Toxicity
Manufacturing
1:24
Addressing patient and family caregivers’ needs after CAR-T therapy
Britt Snoek • 10 Feb 2023
1:29
New HNHCP CAR-T therapy guidelines: an educational resource for nurses and HCPs
Erik Aerts • 9 Feb 2023
0:58
Nursing highlights from the 5th European CAR T-cell Meeting
Michelle Kenyon • 10 Feb 2023
0:59
The importance of nursing education in CAR-T therapy
Elaine Vickers • 10 Feb 2023
View All Videos
2:13
Psychosocial experiences in patients with DLBCL receiving CAR-T therapy vs other therapies
Lorna Warwick • 24 Apr 2023
1:33
The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin • 23 Apr 2023
3:57
Comparing BMT and CAR-T therapy: learnings for patient care and management
Natacha Bolaños • 25 Apr 2023
3:26
Looking forward to the EBMT 2023 Trainee Day
Claire Horgan et al. • 21 Apr 2023
View All Videos
7:03
Addressing the issues of access and affordability to CAR-T therapy
Natacha Bolaños • 25 Apr 2023
3:34
Evaluating the cost and benefits of CAR-T therapy
Mohamad Mohty • 25 May 2023
2:50
Assessing the cost-effectiveness of CAR-T therapy in adult patients with R/R ALL
Monia Marchetti • 26 Apr 2023
2:27
Update on the projects of the GoCART coalition
Christian Chabannon • 23 Apr 2023
View All Videos
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
2:02
Improving treatment options for patients with R/R myeloma: immunotherapies & CELMoDs
Rakesh Popat • 12 May 2023
7:03
Addressing the issues of access and affordability to CAR-T therapy
Natacha Bolaños • 25 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
View All Videos
5:54
Investigating the co-occurrence of CRS and ICANS after CAR-T therapy & the need for novel therapies
Vibhu Agarwal • 13 Feb 2023
2:10
Managing hematologic toxicity associated with CAR-T therapy & insights into the CAR-HEMATOTOX score
Marion Subklewe • 10 Feb 2023
6:38
Comparison of the safety & efficacy of CAR-T therapy vs bispecifics in R/R multiple myeloma
Borja Puertas-Martinez • 8 Oct 2022
6:52
Long-term follow-up of allogeneic stem cell transplantation with omidubicel
Chenyu Lin • 5 Oct 2022
View All Videos
3:51
Donor-derived allogeneic CAR-T for B-ALL post-transplant
Claire Roddie • 7 Dec 2019
1:31
The importance of the European Medicines Agency in CAR-T development
Ulrich Jäger
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al. • 22 Sep 2018
3:08
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi • 12 Sep 2018
View All Videos

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Legend Biotech.

This supporters no influence over the production of the content.

If you are interested in becoming a supporter of The CAR-T & Cellular Therapy Focus, please contact us.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals